After a hiatus, we are ready to return to #radonc journal club. For our March #radonc journal club we will discuss adjuvant chemoradiation in high-risk endometrial cancer. Our article from The Lancet Oncology is:
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomized, phase 3 trial. Lancet Oncol 2018;19:295-309
Dr. Melanie Powell of Clinical Oncology at Barts Health NHS Trust and Dr. Remi Nout of Radiation Oncology at Leiden University Medical Center will join us to discuss at the live journal club Sunday March 18th at 3-4PM Central Standard Time, 8-9 PM GMT. We will start open chat 6 AM CST Saturday March 17th to include global participation.
We will focus on the following topics:
T1. What is the rationale for chemotherapy in high-risk endometrial cancer?
T2. What were the primary endpoints and treatment details of chemoradiotherapy in this study?
T3a. How to the cancer outcomes compare to similar trials evaluating chemoradiotherapy?
T3b. Given the toxicity with radiotherapy with or without chemotherapy, what are the best ways to provide supportive care before, during and after treatment?
T4a. Are there any subsets of patients in PORTEC-3 for whom chemotherapy deserve more clinical trials?
T4b. Are there any good nomograms or molecular markers that help decide whether the higher risks of adjuvant chemotherapy provide enough benefit to consider now?
- Here are guidelines on how to sign up and participate
- Read our disclaimer for ways to keep it rewarding and professional. If you’re not ready, just lurk and tune into the conversation.
Any suggestions on improving the journal club? Do you have other questions? Leave a comment or tweet us at @Rad_Nation. And please join us this weekend!